本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG SAR - Media OutReach Newswire - 21 February 2025 - The Hong Kong Science and Technology Parks Corporation (HKSTP) successfully hosted the "AI in Action" Career Day, attracting over 3,000 visitors. Marking HKSTP's first-ever AI-focused recruitment initiative, the event delivered a one-stop career platform tailored for young professionals and graduates, connecting them with over 150 AI-specialised companies. Together, these innovators showcased 1,000+ roles in cutting-edge fields including software development, data analytics, and large-scale model algorithms, addressing critical talent demands across the AI ecosystem. HKSTP launched the 'Talent Foundry' initiative, bringing together deans and associate deans from the engineering and computer science faculties of the Chinese University of Hong Kong, City University of Hong Kong, Hong Kong Baptist University, Hong Kong Polytechnic University, Hong Kong University of Science and Technology, and the University of Hong Kong. Agile Response to Market Needs and Attracting Top AI Talent The "AI in Action" Career Day was held in a hybrid format (physical and virtual), uniting leading AI enterprises across both platforms. Participants engaged directly with hiring representatives at the venue or explored job vacancies, requirements, and submitted applications via the online "Talent Pool" platform. The event also featured skill-building workshops on jobsearch techniques and personal brand-building, alongside industry insight sessions where participants interacted with experts from global leaders such as NVIDIA, Deloitte AI Institute, and Madhead. These engagements offered deep insights into AI advancements, career pathways, and emerging industry trends. Mr Albert Wong, CEO of HKSTP, said: "We are delighted by the overwhelming turnout, which underscores the industry's strong demand for AI talent. In this era of rapid technological evolution, HKSTP is committed to bridging the gap between technological innovation and top talent. Going forward, we will continue to adapt proactively to market dynamics, leveraging thematic recruitment initiatives to address specific talent needs. We look forward to working hand-in-hand with the next generation of innovators and academic institutions to establish Hong Kong as a key global hub for technological innovation." Launching the 'Talent Foundry' Initiative to Strengthen Collaboration Among Talent, Universities, and Industry To unlock the potential of Hong Kong's students and strengthen the local talent pipeline, HKSTP, in collaboration with engineering and computer science faculties from universities in Hong Kong, launched the "Talent Foundry" initiative to bridge the gap between student skills and job market needs, fostering closer ties between academia and the I&T industry. The official launch brought together deans and associate deans from the Chinese University of Hong Kong, City University of Hong Kong, Hong Kong Baptist University, Hong Kong Polytechnic University, Hong Kong University of Science and Technology, and the University of Hong Kong. Their participation highlights the strong university-industry collaboration fostered by the Talent Foundry initiative. Talent Foundry connects students and graduates with enterprises and startups in the Science Park ecosystem, creating career pathways and providing professional development to immerse young talent in the vibrant I&T community. Through this initiative, HKSTP is committed to nurturing talent and driving Hong Kong's growth as a global innovation hub. HKSTP Recruits Global Tech Talent and Showcases Hong Kong's I&T Opportunities Worldwide Building on the success of the first 'AI In Action' Career Day in 2025, plans are underway to explore additional themed recruitment initiatives such as microelectronics, life and health tech, and financial technology aimed at fostering connections between talent and opportunity in innovative ways. To further expand Hong Kong's I&T talent base and solidify its position as a global hub for top-tier professionals, an HKSTP delegation will embark on a talent recruitment mission to the United Kingdom in March. The delegation will engage with prestigious universities and research institutions to explore collaborative talent development frameworks, while also connecting directly with students through campus engagements. These interactions will showcase Hong Kong's dynamic I&T ecosystem, highlighting diverse internships and high-growth career pathways within the city's thriving innovation landscape. Hashtag: #HKSTP #AIinActionThe issuer is solely responsible for the content of this announcement.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,200 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues contribute in establishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org.
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- In a recent announcement, Bestqool is upgrading both the Pro100 and Pro200 to the four-wavelength configuration (630 nm, 660 nm, 850 nm, 940 nm) as the Pro 300, without increasing the price. Apart from this upgrade, Bestqool has also introduced a second-gen light mobile stand that is more controllable and powerful than its predecessor. Without raising the price, Bestqool updates the Pro100 and Pro200 with a four-wavelength availablity (630, 660, 850, and 940 nm). In addition to this improvement, Bestqool has unveiled a second-generation mobile stand that is stronger and easier to manage. Bestqool is one of the earliest brands in the red light therapy industry, pursuing innovation in product development to meet the emerging needs in health and wellness. These new products further demonstrate how Bestqool is committed to transforming lives by ensuring people have access to high-quality red light therapy at home. Two New Wavelengths Unlocking Diverse Medical Benefits The Pro100 and Pro200 were initially available with two wavelengths, 660 nm and 850 nm, which assist in inflammation reduction and blood circulation. Two new wavelengths have been added with the recent upgrade —630 nm and 940 nm. These new additions stretch the spectrum and make the devices more versatile and able to cater to a wider range of consumer needs. The red light of 630 nm has a better effect on super shallow skin layers, can promote skin repair, and improve skin quality. 940 nm near-infrared light has better penetrating ability, which can penetrate deep tissues, relieve chronic pain, and improve joint function. For users, the availability of these two wavelengths adds more effective therapies targeting multiple pain points and conditions. From mood improvement to ocular fatigue relief, hair growth support, cognitive function aid, and energy and immunity boosting, Bestqool's professional-grade apparatus allows users to physically and mentally lead a healthier, more powerful existence that enables them to live with greater enjoyment in today's speedily changing world. Upgraded mobile stand and powerful panel light ≠ heavy and clumsy Bestqool is dedicated to improving user experience, which is evident from their second-generation mobile stand. This stand provides easy adjustment for large-volume red light devices during home therapy sessions, enhancing safety and comfort while performing therapy. Key Upgrades: Less weight: Easy to handle and carry. More Robust: Designed to withstand the rigors of commercial use. Customer friendly: Better coordination between the customer and the mounted equipment. The 2nd Gen mobile stand is also compatible with 99% of the red light therapy products available today; with its help, even users of other brands devices can have a higher level of use experience. The refined stand facilitates the setup of multiple devices, producing an enjoyable and flexible experience for users. Cost Effectiveness: Major Benefit for Customers One of the standout features of the Pro Series upgrade is that despite adding two other wavelengths, Bestqool has not increased the price of the Pro100 and Pro200. The upgrade ensures that consumers can access cutting-edge, multi-band therapy at the same price level, making it one of the most cost-effective solutions in the world of red light therapy. Also, users don't have to buy multiple devices for their needs. With the updated Pro Series, one device can meet a variety of needs, spanning post-workout recovery, muscle and joint pain relief, skin repair, and enhanced cognitive function. This flexibility allows individuals to explore their health with greater accessibility and cost-effectiveness. The Ingenious Technology Behind the Upgrade The upgraded Pro100 and Pro200 are designed to produce the best results possible, according to the R&D team at Bestqool, who has reportedly left no stone unturned. The following improvements were done: Optimized Spectrum Ratio: The spectrum ratio of 630 nm, 660 nm, 850 nm and 940 nm has been finely tuned to achieve optimal synergy of the four wavelengths. This maintains that each of the wavelengths is colluding to provide maximum therapeutic effects without wasting any energy. This results in a more powerful and efficient device. Dual-Chip Lamp Beads: The Pro100 and Pro200 now employ an innovative dual-chip lamp bead design. This enables the devices to work at the new wavelengths while still providing stable, reliable output. This improves performance without sacrificing longevity or power efficiency of the device. Upgraded Circuit / Improved Heat Dissipation: The devices now feature two additional wavelengths, which require higher power input, leading to excessive heat generation. To ensure the devices stay safe and efficient even at high output conditions, Bestqool has adopted an upgraded version of the circuit design and heat dissipation system. With this upgrade, it ensures smooth and durable performance of Pro Series products for users. Increased Device Longevity: The technical features of the Pro Series contribute to the longevity of the devices. Optimized parts in addition to increased heat dissipation give users the reassurance that these new models will provide safe and effective operation for many years with no performance degradation. About Bestqool With a commitment to providing high-quality red light therapy solutions that are affordable and accessible to all, Bestqool invests significantly in R&D to ensure each product meets the highest standards of both quality and performance. This dedication to constant development and service quality has earned them countless loyal customers as the franchise continues to set the standard in the wellness industry. Market impact and availability There are two main purchasing channels for the products: Amazon and the official website of Bestqool. With warehouses in Europe, America, and Asia, Bestqool assures effective and reliable services to all its customers globally. Additionally, Bestqool offers up to a three-year warranty on its products. This commitment to after-sales service reflects the company's confidence in its quality and helps strengthen relationships with customers. ContactFor media contact and inquiries, please contactGiselleEmail: marketing@Bestqool.com
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by the Therapeutic Goods Administration (TGA), "for the treatment of chronic hypoparathyroidism in adults".1,2 YORVIPATH was granted an Orphan Drug Designation and assessed through the TGA's Priority Review pathway.3,4 It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism. Hypoparathyroidism is a rare, complex endocrine disease, affecting an estimated 6.4-37 per 100,000 people globally.5,6 It is an endocrine disorder in which the production of parathyroid hormone (PTH) by the parathyroid glands is abnormally low or absent, causing low levels of calcium (hypocalcaemia) and high levels of phosphorous (hyperphosphataemia) in the blood.7,8 This impacts proper functioning of nerves and muscles, leading to weakness, muscle spasms or cramps, headaches, hair loss, numbness or tingling, and memory problems.8,9 Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extraskeletal calcifications, and cognitive impairment.10 Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical need for Australian adults diagnosed with chronic hypoparathyroidism. "Until now, the only treatment option for adults with chronic hypoparathyroidism has been conventional therapy with calcium and active vitamin D supplementation to keep blood calcium levels normal," said Professor Ebeling. "While these treatments help to manage the symptoms of hypoparathyroidism, they do not address the underlying deficiency of PTH and contribute to the significant pill burden for patients." "The lack of effective therapeutic options has been an urgent medical need in this area, and the local approval of YORVIPATH represents an important advance in the treatment of chronic hypoparathyroidism in Australia," said Professor Ebeling. YORVIPATH is a first-in-class PTH replacement therapy. A prodrug of parathyroid hormone (PTH [1-34]), YORVIPATH is administered subcutaneously once daily, with sustained release of active PTH designed to provide PTH levels in the physiological range for 24 hours/day.11 YORVIPATH's approval in Australia was supported by the results of Ascendis Pharma's Phase 3 PaTHway trial, a 26-week randomised, double-blind, placebo-controlled study with a 156-week open-label extension, published in the Journal of Bone and Mineral Research.12 Involving 84 adults with chronic hypoparathyroidism, the clinical trial demonstrated the efficacy, safety and tolerability of YORVIPATH as a once-daily PTH replacement therapy. Data from the pivotal trial showed 93% (57/61) of YORVIPATH-treated patients achieved independence from both active vitamin D and therapeutic doses of elemental calcium, which was associated with a clinically meaningful reduction in their daily pill burden.12 The safety analysis demonstrated YORVIPATH was generally well-tolerated, with the most frequently reported adverse reactions being injection site reactions (21.6%), headache (18.7%), and paraesthesia (13.7%).2 In addition to the significant short-term and long-term medical complications of chronic hypoparathyroidism, individuals diagnosed with the condition also experience reduced health-related quality of life, including the negative impact of symptoms on their daily life and work productivity.12 Chief Executive Officer of the Australian Thyroid Foundation (ATF), Beverley Garside, acknowledged the significance of the TGA approval in offering adults living with chronic hypoparathyroidism the opportunity to improve their health and wellbeing. However, she reinforced that this is not the time for complacency, as it is just the first step towards securing subsidised access to an important new treatment option for this community. "As the leading national voice for good thyroid health in Australia, the ATF recognises the importance of the TGA registration of YORVIPATH as a new treatment option for the hypoparathyroid community. While this is positive news, it is only the first step," said Ms Garside. "For adults diagnosed with chronic hypoparathyroidism to truly benefit from this new treatment, it is essential they have the option of subsidised and affordable access to YORVIPATH through the Pharmaceutical Benefits Scheme as quickly as possible." YORVIPATH is being made available in Australia by Specialised Therapeutics (ST), under an exclusive distribution agreement with global biopharmaceutical company Ascendis Pharma A/S that covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. The Australian registration of YORVIPATH follows approvals issued to Ascendis Pharma by the United States Food and Drug Administration (US FDA)13 in August 2024 and the European Medicines Agency (EMA)14 in November 2023. "The Australian approval of YORVIPATH reflects our values and dedication to applying science to help address the significant unmet medical needs expressed by the hypoparathyroidism community," said Roy Khoury, Vice President, Head of International Markets at Ascendis Pharma. "We are pleased to partner with Specialised Therapeutics to broaden access to this innovative therapy, based on our TransCon technology, which offers a new approach to the treatment of this often-debilitating rare disease." ST Chief Executive Officer, Mr Carlo Montagner, said the approval of YORVIPATH was a meaningful milestone, but the company would not stop until it achieved reimbursement for eligible Australians with hypoparathyroidism through the Pharmaceutical Benefits Scheme (PBS). "We are proud to have brought the first and only TGA-registered treatment for chronic hypoparathyroidism to Australians living with the condition so rapidly following the recent FDA and EMA approvals," said Mr Montagner. "Chronic hypoparathyroidism has considerable and life-long wide-ranging impacts on these individuals and we are committed to working with the local hypoparathyroidism community and the Australian Government to ensure YORVIPATH is accessible to eligible patients through the PBS at the earliest opportunity." YORVIPATH will be reviewed by the Pharmaceutical Benefits Advisory Committee (PBAC) at its first meeting of the year, to be held from 12-14 March 2025. YORVIPATH will be made available for prescribing in Australia once it has been listed on the PBS. PBS Information: YORVIPATH is not listed on the Pharmaceutical Benefits Scheme (PBS). About Specialised Therapeutics Founded in 2007, Specialised Therapeutics is the region's largest independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information can be found at www.stbiopharma.com About Ascendis Pharma Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit: ascendispharma.com to learn more. About Hypoparathyroidism10 Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestines. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes. About PaTHway12 The PaTHway trial was a double-blind, placebo-controlled, 26-week, Phase 3 study that assessed the efficacy and safety of PTH replacement therapy with palopegteriparatide for individuals with hypoparathyroidism. Participants (n=84) were randomised 3:1 to once-daily palopegteriparatide (initially 18 μg/d) or placebo, both co-administered with conventional therapy. The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin-adjusted serum calcium levels (8.3–10.6 mg/dL), independence from conventional therapy (requiring no active vitamin D and ≤600 mg/d of calcium), and no increase in study drug over 4 weeks before week 26. At week 26, 79% (48/61) of participants treated with palopegteriparatide versus 5% (1/21) with placebo met the composite primary efficacy endpoint (p < 0.0001). Additionally, 93% (57/61) of participants treated with palopegteriparatide achieved independence from conventional therapy. Palopegteriparatide treatment normalised mean 24-hour urine calcium. Overall, 82% (50/61) treated with palopegteriparatide and 100% (21/21) with placebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug-related withdrawals occurred. About YORVIPATH® (palopegteriparatide) YORVIPATH® (palopegteriparatide, developed as TransCon™ PTH) is a once-daily prodrug providing sustained release of active PTH. It was approved by the European Union as a parathyroid hormone (PTH) replacement therapy for the treatment of adults with chronic hypoparathyroidism15 and the United States for the treatment of hypoparathyroidism in adults13. Treatment should be initiated and monitored by physicians or qualified healthcare professionals experienced in the diagnosis and management of patients with hypoparathyroidism. Yorvipath® is a registered trademark of Ascendis Pharma A/S (NASDAQ: ASND). References: Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG). Available at: https://www.tga.gov.au/australian-register-therapeutic-goods. [Accessed Dec 2024]. YORVIPATH (palopegteriparatide) AU Product Information. Therapeutic Goods Administration. Prescription medicine determinations and designations: Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd) – Orphan drug designation. Available at: https://www.tga.gov.au/resources/designations-determinations/notice-palopegteriparatide-specialised-therapeutics-pharma-pty-ltd. [Accessed Dec 2024]. Therapeutic Goods Administration. Prescription medicine determinations and designations: Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd) – Priority review. Available at: https://www.tga.gov.au/resources/designations-determinations/notice-palopegteriparatide-specialised-therapeutics-pharma-pty-ltd-0. [Accessed Dec 2024]. Siggelkow H, Pacaud D, et al. Clin Endocrinol (Oxf). 2020;92(2). Bjornsdottir S, Sikjaer T, et al. J Bone Miner Res. 2022;37(12). Australian Thyroid Foundation. Thyroid Facts: Parathyroid Glands – Hypoparathyroidism. Available at: https://thyroidfoundation.org.au/Parathyroid-Glands [Accessed Dec 2024]. National Organization for Rare Disorders. Disease Overview: Hypoparathyroidism - Symptoms, Causes, Treatment, 14 August 2024. Available at: https://rarediseases.org/rare-diseases/hypoparathyroidism/ [Accessed Dec 2024]. Endocrine Society. Endocrine Library: Patient Resources; Hypoparathyroidism, 24 January 2022. Available at: https://www.endocrine.org/patient-engagement/endocrine-library/hypoparathyroidism [Accessed Dec 2024]. Bilezikian JP. J Clin Endocrinol Metab. 2020;105(6):1722-1736. doi:10.1210/clinem/dgaa113. YORVIPATH (palopegteriparatide) US Prescribing Information. Khan AA, Bilezikian JP, Cusano NE, et al. J Bone Miner Res. 2023;38(1). US Food and Drug Administration. FDA approves new drug for hypoparathyroidism, a rare disorder, 9 August 2024. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-hypoparathyroidism-rare-disorder [Accessed Dec 2024]. European Medicines Agency. Yorvipath: Palopegteriparatide, 17 November 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/yorvipath [Accessed Dec 2024]. YORVIPATH (palopegteriparatide).EU Summary of Product Characteristics.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence. Under the collaboration agreement, the parties will combine Harbour BioMed's industry-leading technology platform, proprietary dataset and extensive expertise in antibody development with Insilico's advanced capabilities in designing integrated AI-driven drug discovery and development platforms to jointly develop the next-generation AI-powered antibody application. Additionally, the two companies will collaborate on early-stage drug discovery programs targeting novel, specific antibodies, leveraging Insilico's AI expertise and Harbour BioMed's wet lab capabilities. These efforts aim to deliver innovative therapeutic solutions for the unmet medical needs of immunology, oncology, and neuroscience. Harbour BioMed has built a strong foundation in antibody discovery and development, underpinned by its advanced technology platform, proprietary dataset, and deep expertise. The Company's proprietary Harbour Mice® platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanization. The HCAb technology, in particular, produces unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. With a clinically validated and globally recognized platform, Harbour BioMed has applied its technology in more than 250 drug discovery programs across various therapeutic areas, establishing itself as a leader in the field of biotherapeutics. Insilico has previously showcased the capability of its proprietary AI platform to significantly reduce cost and improve efficiency in the early stages of small molecule drug discovery and development. Since 2021, the company has established a wholly-owned pipeline of 30 assets powered by its Pharma.AI platform, 10 of which have received IND clearance, setting a benchmark for AI-driven drug discovery and development. In July 2024, Insilico introduced Generative Biologics, an AI-powered tool for de novo protein engineering, designed to accelerate the development of next-generation biologics. Moving forward, the company plans to leverage real-world case studies to further refine and advance the application through ongoing enhancements and iterative improvements. "We are excited to collaborate with Insilico, a pioneer and leading advocate in AI-driven drug discovery and development, to integrate AI technologies with our industry-leading technology platform and proven expertise in antibody discovery and development," said Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed. "By combining our validated Harbour Mice® platform with advanced generative AI approaches, we aim to further streamline antibody discovery, enhance candidate selection, and ultimately bring innovative therapies to patients more efficiently." "By combining advanced machine learning models with biological expertise, AI platforms are transforming antibody discovery and engineering - enabling the prediction of antibody structures, identification of binding sites, and design of candidates with enhanced specificity, efficacy, and safety," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "High-quality dataset and wet-lab validation are critical components in this process, and we are thrilled to collaborate with Harbour BioMed who excel in these areas. Together, we aim to build the next generation AI-driven antibody platforms and deliver breakthrough antibody therapies to address critical healthcare needs." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions. The proprietary antibody technology platform Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com. About Insilico Medicine Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
CAMBRIDGE, Mass., Feb. 20, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with the University of Alabama at Birmingham (UAB) to support their research in B cell development. Under the terms of the agreement, UAB, represented by Dr. James Kobie, has been granted a non-exclusive license to use Nona's H2L2 Harbour Mice® platform to develop fully human antibodies. This will enable UAB researchers to pursue breakthroughs in B cell development work. Dr. Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, commented, "Many transformative therapies originate from academic laboratories. We are excited to support UAB's research efforts. This highlights our commitment to leveraging our antibody discovery technologies to bridge the gap between scientific discovery and real-world therapeutic applications, addressing unmet medical needs and benefiting patients worldwide." Dr. James Kobie, PhD, Associate Professor in the Division of Infectious Disease at the UAB School of Medicine, said, "We hope — through our research — to address fundamental questions about the human B cell receptor repertoire and develop monoclonal antibodies with therapeutic and diagnostic potential for infectious disease and oncology targets." About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from "Idea to IND" (I to I™), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New IndicationsKRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leading biotechnology company specializing in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an innovative exosome-based injectable therapeutic. This agreement marks the first major licensing deal for an exosome therapeutic in Korea, signifying a major milestone in the commercialization of exosome-based medicines. Advancing Exosome Therapeutics for New Indications BxC-I17e is a key asset in Brexogen's pipeline and is currently undergoing clinical trials in the United States for atopic dermatitis. Recognizing its broader therapeutic potential, BMI Korea has secured rights to expand its development into potential indications excluding immunological indications, covering both domestic and key export markets. While financial terms remain confidential, Brexogen will receive: KRW 3 billion (approximately USD 2.3 million) as a non-refundable upfront payment Milestone payments linked to clinical, regulatory, and commercial progress Double-digit percentage royalties on annual net salesAdditionally, Brexogen will share in future licensing revenues should BMI Korea pursue further out-licensing agreements with third parties. Strategic Collaboration to Accelerate Market Entry BMI Korea, a pharmaceutical company with annual revenues exceeding KRW 100 billion (USD 77 million), specializes in prescription drugs, biologics, medical devices, and aesthetic products. The company operates large-scale contract manufacturing (CMO) facilities in Jeju and Osong, Chungbuk, with extensive expertise in regulatory approvals, production, and commercialization. Under this partnership, BxC-I17e will be manufactured at BMI Korea's cutting-edge facilities, ensuring scalability for both clinical and commercial supply. "Partnering with BMI Korea is a significant step forward for Brexogen," said a Brexogen representative. "Their robust pharmaceutical manufacturing expertise provides a strong foundation for the commercialization of BxC-I17e, allowing us to accelerate market entry while ensuring high-quality production." A BMI Korea spokesperson added:"This agreement positions BMI Korea as a leader in exosome-based therapeutics. By securing one of the most advanced pipelines in the industry, we are poised to achieve Korea's first regulatory approval for an exosome therapy and expand our biopharmaceutical portfolio." A Breakthrough for the Exosome Therapeutics Industry To date, globally, there is no approved exosome-based therapeutics for commercial use. This partnership is expected to drive innovation in exosome drug development and set new industry standards. Founded in 2019, Brexogen is a biotechnology company pioneering Natural Biomacromolecule Cargo-Controlled Exosome Technology for therapeutics, medical devices, and aesthetic applications. The company's flagship program, BRE-AD01 for atopic dermatitis, is currently in Phase 1 clinical trials in the U.S.. Brexogen has also successfully commercialized BREXTEM-S (for skin rejuvenation) and BREXTEM-H (for hair restoration), offering exosome-based solutions for clinical and hospital use. Looking ahead, Brexogen is actively preparing for its KOSDAQ listing in 2026, with Korea Investment & Securities serving as the lead underwriter. This agreement between Brexogen and BMI Korea is expected to accelerate the clinical and commercial adoption of exosome-based therapeutics, paving the way for groundbreaking advancements in regenerative medicine. About Brexogen Brexogen is a biotechnology company specializing in exosome-based therapeutics for a range of medical and aesthetic applications. Utilizing its proprietary Natural Biomacromolecule Cargo-Controlled Exosome Platform, the company is focused on developing next-generation exosome therapies and is actively advancing clinical research to establish exosomes as a new standard in regenerative medicine. About BMI Korea BMI Korea is a leading pharmaceutical manufacturing and sales company, with expertise in contract manufacturing, regulatory approvals, and global distribution. The company operates large-scale biopharmaceutical and medical device production facilities and is committed to advancing innovative therapies for unmet medical needs.
Biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
